Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression
Standard
Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression. / Hagel, Christian; Treszl, András; Fehlert, Julia; Harder, Jonas; von Haxthausen, Franziska; Kern, Meike; von Bueren, André O.; Kordes, Uwe.
In: J NEURO-ONCOL, Vol. 112, No. 2, 01.04.2013, p. 191-7.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Supra- and infratentorial pediatric ependymomas differ significantly in NeuN, p75 and GFAP expression
AU - Hagel, Christian
AU - Treszl, András
AU - Fehlert, Julia
AU - Harder, Jonas
AU - von Haxthausen, Franziska
AU - Kern, Meike
AU - von Bueren, André O.
AU - Kordes, Uwe
PY - 2013/4/1
Y1 - 2013/4/1
N2 - Ependymomas comprise 8 % of all intracranial tumors in children <15 years. Recent studies revealed that some supratentorial ependymomas express neuronal antigens and that high expression of neurofilament protein light polypeptide (NEFL) correlates with better clinical outcome. We retrospectively analyzed an expanded panel of proteins in 6 supratentorial, 15 posterior fossa and 4 spinal pediatric ependymomas by immunohistochemistry. Expression of high and low affinity neurotrophin receptors TrkA (NTRK1) and p75 (NGFR), pan-neuronal markers NeuN (RBFOX3) and synaptophysin, radial glial marker SOX9, adhesion molecules CD56 (NCAM) and CD44, junctional protein connexin 43 (GJA1), glial fibrillary acidic protein (GFAP), epithelial membrane antigen and proliferation associated antigen Ki-67 were evaluated in a semi-quantitative or quantitative (Ki-67 and NeuN-index) fashion. We found p75 and NeuN to be expressed at significantly higher levels in supratentorial versus infratentorial tumors and GFAP to be expressed at significantly higher levels in infratentorial lesions. In conclusion, immunohistochemical expression of p75, NeuN and GFAP differed in ependymomas depending on tumor topography supporting the view of divergent cells of origin. However, because of the small sample size the results are of preliminary nature and replication in a larger cohort would be desirable.
AB - Ependymomas comprise 8 % of all intracranial tumors in children <15 years. Recent studies revealed that some supratentorial ependymomas express neuronal antigens and that high expression of neurofilament protein light polypeptide (NEFL) correlates with better clinical outcome. We retrospectively analyzed an expanded panel of proteins in 6 supratentorial, 15 posterior fossa and 4 spinal pediatric ependymomas by immunohistochemistry. Expression of high and low affinity neurotrophin receptors TrkA (NTRK1) and p75 (NGFR), pan-neuronal markers NeuN (RBFOX3) and synaptophysin, radial glial marker SOX9, adhesion molecules CD56 (NCAM) and CD44, junctional protein connexin 43 (GJA1), glial fibrillary acidic protein (GFAP), epithelial membrane antigen and proliferation associated antigen Ki-67 were evaluated in a semi-quantitative or quantitative (Ki-67 and NeuN-index) fashion. We found p75 and NeuN to be expressed at significantly higher levels in supratentorial versus infratentorial tumors and GFAP to be expressed at significantly higher levels in infratentorial lesions. In conclusion, immunohistochemical expression of p75, NeuN and GFAP differed in ependymomas depending on tumor topography supporting the view of divergent cells of origin. However, because of the small sample size the results are of preliminary nature and replication in a larger cohort would be desirable.
KW - Adolescent
KW - Antigens, Nuclear
KW - Child
KW - Child, Preschool
KW - Ependymoma
KW - Female
KW - Follow-Up Studies
KW - Glial Fibrillary Acidic Protein
KW - Humans
KW - Immunoenzyme Techniques
KW - Infant
KW - Infratentorial Neoplasms
KW - Male
KW - Neoplasm Grading
KW - Nerve Tissue Proteins
KW - Prognosis
KW - Receptors, Nerve Growth Factor
KW - Retrospective Studies
KW - Supratentorial Neoplasms
KW - Tumor Markers, Biological
U2 - 10.1007/s11060-013-1062-1
DO - 10.1007/s11060-013-1062-1
M3 - SCORING: Journal article
C2 - 23371454
VL - 112
SP - 191
EP - 197
JO - J NEURO-ONCOL
JF - J NEURO-ONCOL
SN - 0167-594X
IS - 2
ER -